marker is known for detection of asymptomatic disease in selected populations or for prognostic purposes or treatment monitoring. We identified immunogenic proteins as tumormarkers for RCC by combining con-ventional proteome analysis with serological screening, andwe investigated the diagnostic clinical value of such markers in serum. METHODS: We studied the immunogenic protein ex-pression profile of CAL 54, a human RCC cell line, by 2-dimensional electrophoresis combined with immu-noblotting using sera from healthy donors compared with RCC patients.We developed a homogeneous, flu-orescent, dual-monoclonal immunoassay for metallo-proteinase 7 (MMP-7) and used it to measure MMP-7 in sera from 30 healthy donors, 30 RCC patients, an
The timely diagnosis and therapeutic monitoring of human renal cell carcinoma (RCC) is limited by th...
The role of matrilysin 1 or matrix metalloproteinase-7 (MMP-7) in cancer is extremely complex and po...
Renal cell carcinoma (RCC) represents 2.2% of all cancer incidences; however, prognostic or predicti...
marker is known for detection of asymptomatic disease in selected populations or for prognostic purp...
International audienceBACKGROUND: No validated renal cell carcinoma (RCC) marker is known for detect...
211-218Diagnostic biomarkers for early detection of renal cell carcinoma (RCC) are in great need. I...
Renal cell carcinoma (RCC) is relatively resistant to conventional chemotherapy and radiotherapy. Ho...
PURPOSE: Despite encouraging results in other cancers, in renal cell cancer, no consensus exists reg...
Renal cell carcinoma (RCC) is one of the most lethal urologic cancers and about 80% of RCC are of th...
A method that relies on subtractive tissue-directed shot-gun proteomics to identify tumor proteins i...
OBJECTIVE: To investigate discriminating protein patterns and serum biomarkers between clear cell re...
Objective: To investigate discriminating protein patterns and serum biomarkers between clear cell re...
<strong></strong>Plasma proteome from patients with renal cell carcinoma (RCC) and controls underwen...
OBJECTIVES To investigate the possibility of using the ClinProt technique to find serum cancer relat...
In cancer management early diagnosis is crucial for successful treatment. Unfortunately, patients mo...
The timely diagnosis and therapeutic monitoring of human renal cell carcinoma (RCC) is limited by th...
The role of matrilysin 1 or matrix metalloproteinase-7 (MMP-7) in cancer is extremely complex and po...
Renal cell carcinoma (RCC) represents 2.2% of all cancer incidences; however, prognostic or predicti...
marker is known for detection of asymptomatic disease in selected populations or for prognostic purp...
International audienceBACKGROUND: No validated renal cell carcinoma (RCC) marker is known for detect...
211-218Diagnostic biomarkers for early detection of renal cell carcinoma (RCC) are in great need. I...
Renal cell carcinoma (RCC) is relatively resistant to conventional chemotherapy and radiotherapy. Ho...
PURPOSE: Despite encouraging results in other cancers, in renal cell cancer, no consensus exists reg...
Renal cell carcinoma (RCC) is one of the most lethal urologic cancers and about 80% of RCC are of th...
A method that relies on subtractive tissue-directed shot-gun proteomics to identify tumor proteins i...
OBJECTIVE: To investigate discriminating protein patterns and serum biomarkers between clear cell re...
Objective: To investigate discriminating protein patterns and serum biomarkers between clear cell re...
<strong></strong>Plasma proteome from patients with renal cell carcinoma (RCC) and controls underwen...
OBJECTIVES To investigate the possibility of using the ClinProt technique to find serum cancer relat...
In cancer management early diagnosis is crucial for successful treatment. Unfortunately, patients mo...
The timely diagnosis and therapeutic monitoring of human renal cell carcinoma (RCC) is limited by th...
The role of matrilysin 1 or matrix metalloproteinase-7 (MMP-7) in cancer is extremely complex and po...
Renal cell carcinoma (RCC) represents 2.2% of all cancer incidences; however, prognostic or predicti...